KaloBios Seeks Appeal Of Nasdaq Delisting
This article was originally published in Scrip
Executive Summary
KaloBios Pharmaceuticals Inc. on Dec. 29 said it is appealing the Nasdaq's decision to delist the company's securities from the stock market.